KR100596260B1 - 세포-매개된 면역 질환 치료용 약제 - Google Patents

세포-매개된 면역 질환 치료용 약제 Download PDF

Info

Publication number
KR100596260B1
KR100596260B1 KR1020007001813A KR20007001813A KR100596260B1 KR 100596260 B1 KR100596260 B1 KR 100596260B1 KR 1020007001813 A KR1020007001813 A KR 1020007001813A KR 20007001813 A KR20007001813 A KR 20007001813A KR 100596260 B1 KR100596260 B1 KR 100596260B1
Authority
KR
South Korea
Prior art keywords
delete delete
eczema
retinoic acid
pharmaceutically acceptable
cis retinoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020007001813A
Other languages
English (en)
Korean (ko)
Other versions
KR20010023186A (ko
Inventor
볼락베르너
오트프리츠
Original Assignee
바실리어 파마슈티카 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100596260(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바실리어 파마슈티카 아게 filed Critical 바실리어 파마슈티카 아게
Publication of KR20010023186A publication Critical patent/KR20010023186A/ko
Application granted granted Critical
Publication of KR100596260B1 publication Critical patent/KR100596260B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020007001813A 1997-08-23 1998-08-18 세포-매개된 면역 질환 치료용 약제 Expired - Lifetime KR100596260B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97114651A EP0908179A1 (en) 1997-08-23 1997-08-23 Treatment of cell-mediated immune diseases
EP97114651.9 1997-08-23
PCT/EP1998/005236 WO1999009969A1 (en) 1997-08-23 1998-08-18 Treatment of cell-mediated immune diseases

Publications (2)

Publication Number Publication Date
KR20010023186A KR20010023186A (ko) 2001-03-26
KR100596260B1 true KR100596260B1 (ko) 2006-07-03

Family

ID=8227266

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007001813A Expired - Lifetime KR100596260B1 (ko) 1997-08-23 1998-08-18 세포-매개된 면역 질환 치료용 약제

Country Status (18)

Country Link
US (2) US6589989B1 (enExample)
EP (2) EP0908179A1 (enExample)
JP (1) JP3522220B2 (enExample)
KR (1) KR100596260B1 (enExample)
CN (1) CN1136845C (enExample)
AT (1) ATE259224T1 (enExample)
AU (1) AU739440B2 (enExample)
BR (1) BRPI9811989B8 (enExample)
CA (1) CA2301907C (enExample)
DE (1) DE69821624T2 (enExample)
DK (1) DK1007020T3 (enExample)
ES (1) ES2214729T3 (enExample)
NO (1) NO327141B1 (enExample)
NZ (1) NZ502812A (enExample)
PT (1) PT1007020E (enExample)
RU (1) RU2238083C2 (enExample)
TR (1) TR200000488T2 (enExample)
WO (1) WO1999009969A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
FR2834216B1 (fr) * 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
TW579640B (en) * 2002-10-23 2004-03-11 Veutron Corp Light gathering device of scanner
EP1527774A1 (en) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP2327401A3 (en) * 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
ES2449494T3 (es) 2003-04-11 2014-03-20 Glaxo Group Limited Procedimiento para la producción de ácido 9-cis-retinoico
US7122751B1 (en) * 2004-01-16 2006-10-17 Cobalt Flux Switch apparatus
CN1921843A (zh) * 2004-01-23 2007-02-28 独立行政法人科学技术振兴机构 含视黄酸的糖尿病治疗药
AU2015207903B2 (en) * 2004-06-18 2017-08-17 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
JP5166026B2 (ja) 2004-06-18 2013-03-21 ユニバーシティ オブ ワシントン 視力障害の治療のためのレチナール誘導体およびその使用方法
AU2012216808B2 (en) * 2004-06-18 2015-04-30 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
CN101262861B (zh) * 2005-09-09 2011-04-06 有限会社肯菲思 用于预防及/或治疗肠疾病的药物
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
US8580278B2 (en) * 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
JP5663025B2 (ja) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CA2796991A1 (en) 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN102247348A (zh) * 2011-05-23 2011-11-23 天津拓飞生物科技有限公司 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
MX370928B (es) 2012-03-01 2020-01-08 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US9221854B2 (en) 2012-08-17 2015-12-29 Basf Se Isomerization of olefinic compounds
KR102138561B1 (ko) 2012-08-17 2020-07-28 바스프 에스이 올레핀계 화합물의 이성질화
US20150202172A1 (en) * 2014-01-22 2015-07-23 Glaxo Group Limited Novel method of use
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN113499335B (zh) * 2021-07-13 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种靶向自噬融合治疗神经退行性疾病的药物
WO2025108208A1 (zh) * 2023-11-21 2025-05-30 南京纽邦生物科技有限公司 用于改善或维持皮肤、毛囊、头皮或毛发健康的方法和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5932622A (en) * 1991-12-18 1999-08-03 The Salk Institute For Biological Studies Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid
KR100274101B1 (ko) 1992-01-22 2000-12-15 프리돌린 클라우스너, 롤란드 비. 보레르 9-시스 레틴산을 함유하는 약제학적 조성물
US5750570A (en) * 1992-03-31 1998-05-12 The Regents Of The University Of Michigan Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
TW272187B (enExample) * 1992-05-20 1996-03-11 Hoffmann La Roche
WO1994022818A1 (en) * 1993-04-05 1994-10-13 Pfizer Inc. Method for the preparation of 9-cis retinoic acid
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
DE4415204A1 (de) * 1994-04-30 1995-11-02 Carl Heinrich Dr Weischer Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US6083977A (en) * 1994-12-30 2000-07-04 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders

Also Published As

Publication number Publication date
NO327141B1 (no) 2009-05-04
EP1007020B1 (en) 2004-02-11
DE69821624T2 (de) 2004-09-23
AU9435698A (en) 1999-03-16
US6589989B1 (en) 2003-07-08
CA2301907C (en) 2009-02-10
BR9811989A (pt) 2000-09-05
NO20000870L (no) 2000-02-22
DE69821624D1 (de) 2004-03-18
JP3522220B2 (ja) 2004-04-26
BRPI9811989B8 (pt) 2021-05-25
RU2238083C2 (ru) 2004-10-20
WO1999009969A1 (en) 1999-03-04
TR200000488T2 (tr) 2000-07-21
CA2301907A1 (en) 1999-03-04
PT1007020E (pt) 2004-05-31
JP2003526595A (ja) 2003-09-09
AU739440B2 (en) 2001-10-11
DK1007020T3 (da) 2004-06-07
EP1007020A1 (en) 2000-06-14
NZ502812A (en) 2002-05-31
NO20000870D0 (no) 2000-02-22
CN1268886A (zh) 2000-10-04
US20040039056A1 (en) 2004-02-26
ES2214729T3 (es) 2004-09-16
KR20010023186A (ko) 2001-03-26
CN1136845C (zh) 2004-02-04
EP0908179A1 (en) 1999-04-14
ATE259224T1 (de) 2004-02-15
BRPI9811989B1 (pt) 2015-12-15

Similar Documents

Publication Publication Date Title
KR100596260B1 (ko) 세포-매개된 면역 질환 치료용 약제
EP0391033B1 (en) Retinal, derivatives and their therapeutic use
US4201788A (en) Process for alleviating proliferative skin diseases
CN1123523A (zh) 用橙皮甙元控制皮脂和治疗痤疮的方法
HU212734B (en) Process for producing pharmaceutical compositions comprising 9-cis-retinoic acid
CN101489541A (zh) 多胺在治疗银屑病中的应用
US11819486B2 (en) Composition for external use on skin for inflammatory diseases
CA2282682C (en) Tazarotene and corticosteroid treatment for psoriasis
US5362719A (en) Use of vitamin-D analogues in the treatment of acne
JPH09509139A (ja) 酪酸エステル細胞分化薬
EP1839656A1 (en) Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
JP3839502B2 (ja) 湿疹・皮膚炎群治療剤
EP3773641B1 (en) Topical pharmaceutical compositions for treating skin conditions
US8541469B2 (en) Treatment of cell-mediated immune diseases
JPH08295628A (ja) 脱毛症外用治療剤
MXPA00001803A (en) Treatment of cell-mediated immune diseases
US9731021B2 (en) Hydrogel composition for the treatment of dermatological disorders
US20230320984A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
JPWO2020116570A1 (ja) 皮膚外用剤
HK40037195B (en) Topical pharmaceutical compositions for treating skin conditions
HK40037195A (en) Topical pharmaceutical compositions for treating skin conditions
CN1043628A (zh) 缓解静脉扩张的组合物及其制备方法
JPWO2022229934A5 (enExample)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20030317

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030818

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050518

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050518

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20060203

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20060103

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20060403

Appeal identifier: 2006101000972

Request date: 20060203

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20060203

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20060203

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050916

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20030818

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20060403

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20060316

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060626

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060623

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090623

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100625

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110519

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20120611

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130531

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130531

Start annual number: 8

End annual number: 8

PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20130715

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20140529

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140529

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20150330

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160330

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170330

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190624

Start annual number: 14

End annual number: 14

PC1801 Expiration of term